NCT01381094View on ClinicalTrials.gov

42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

PHASE2CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

June 15, 2011

Primary Completion Date

February 16, 2012

Study Completion Date

February 16, 2012

Conditions
AnemiaKidney Disease
Interventions
DRUG

AKB-6548

oral dose administered once daily for 42 days

DRUG

Placebo

oral Placebo administered once daily for 42 days

Trial Locations (28)

Unknown

Pine Bluff

Covina

Los Angeles

Lynwood

Riverside

San Dimas

Whittier

Coral Springs

Lauderdale Lakes

Miami

Ocala

Augusta

Macon

Wichita

Shreveport

Springfield

Detroit

Pontiac

Warren

Bethpage

Mineola

Wilmington

Oklahoma City

Knoxville

Austin

Fort Worth

Houston

San Antonio

Sponsors
All Listed Sponsors
lead

Akebia Therapeutics

INDUSTRY